Drug development is an expensive and time-consuming process. Usage of sub-optimal preclinical models can also lead to delays in gaining regulatory approval for many drugs. Animal models, once the gold-standard, are falling out of favour because they do not accurately represent the human body and are neither ethical nor sustainable. There is an increasing demand for patient-specific models that can more accurately recapitulate the physiological state of diseased tissue. Consequently, newer technologies such as organoids and spheroids are replacing animal models. In this spotlight talk, I will highlight our contributions to the development of relevant disease models for drug discovery, by sharing two interesting studies using Takara Bio solutions.
To view the video assoicated with this lecture